George is happy to announce a new content series: “Molecule Builder”. Here he will be highlighting selected sets of Building Blocks from which can be used as starting materials for analog-synthesis of approved drug molecules.


Mavacamten is the first cardiac myosin inhibitor, newly approved by the FDA for the treatment of obstructive hypertrophic cardiomyopathy (HCM).

The last step in Mavacamten synthesis is a reaction of a primary amine with N-substituted 1,2,3,4-tetrahydropyrimidine-2,4-dione halogen derivative.

Two selected sets of Building Blocks, which contain both parts:


N-substituted 1,2,3,4-tetrahydropyrimidine-2,4-diones (1796 cmpds), and  Primary amines (771 cmpds),


might be a perfect start for your research!